Market Performance Overview
At 11:41 AM Central Europe on Wednesday, 21 April 2026, shares of Vivos Therapeutics (ticker VVOS) closed 4.44 % higher than the previous 24‑hour trading period. The current trading price of a single Vivos share sits at approximately USD 0.14, a modest valuation that reflects the company’s niche focus within the sleep‑disordered breathing market.
With a supply of 20.1 million shares and a market capitalisation of USD 2.7 million, Vivos Therapeutics has seen a 11.88 % decline since the close of the last month. Nevertheless, the recent uptick has generated about USD 10.8 million in trading volume over the past day. The 200‑day simple moving average (SMA) stands at USD 0.83, indicating that the current price is well below its longer‑term trend line. The most recent high in the past 52 weeks was USD 3.10 (24 October 2025), while the 52‑week low is USD 0.12 (20 October 2026).
Strategic Partnership with SOD Sciences
Vivos Therapeutics has announced a strategic alliance with SOD Sciences, a move that carries significant implications for both companies’ product pipelines and market reach:
- Equity and Share Structure – Vivos will acquire an 11 % equity stake in SOD Sciences by issuing 12,000 shares of its Series C Convertible Preferred Stock, foregoing any immediate cash outlay.
- Co‑Ownership of a Pseudohypoxia Early‑Warning Test – The partnership includes a 50 % joint ownership of a novel pseudohypoxia test designed to detect sleep‑related disturbances that may signal underlying chronic disease.
- Revenue and Cost Sharing – Both companies will split revenue and intellectual‑property costs associated with the test equally, creating a balanced financial relationship.
- Joint Marketing and Distribution – Vivos will be able to bundle its sleep‑apnea treatments with SOD’s ReBalU Protocol and the shared test, positioning the combined offering in sleep centres, clinics, and assisted‑living facilities across the United States. This arrangement is expected to unlock new revenue streams while broadening Vivos’s product portfolio.
The alliance is strategically aligned with Vivos Therapeutics’ mission to “revolutionise the treatment of sleep‑related respiratory disorders” by combining complementary technologies and expanding access to a wider patient base.
Contextualising Sector Activity
The broader biotech and diagnostics sector has shown varied activity in the past 24 hours:
| Company | Ticker | 24‑hr % Move | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Ernexa Therapeutics | ERNA | +13.13 % | USD 2.24 | USD 3.2 million |
| Bluejay Diagnostics | BJDX | –3.59 % | USD 0.67 | USD 3.1 million |
| Calidi Biotherapeutics | CLDI | –1.66 % | USD 0.77 | USD 2.9 million |
| Airwa | YYAI | +1.34 % | USD 0.68 | USD 3.1 million |
| Gri Bio | GRI | +0.69 % | USD 1.46 | USD 3.2 million |
These movements illustrate the volatility that can accompany small‑cap biotech stocks, with significant price swings occurring even within a single trading day. Vivos Therapeutics’ recent 4.44 % gain sits comfortably within this broader pattern of sector dynamism.
Company Profile
Vivos Therapeutics, Inc. operates within the Health Care sector and is headquartered in Highlands Ranch, United States. The company specializes in the development of medical technologies for patients suffering from sleep‑disordered breathing and obstructive sleep apnea. Its focus on innovative solutions aims to enhance the quality of life for patients experiencing sleep‑related respiratory disorders. Vivos Therapeutics is listed on the Nasdaq stock exchange and serves customers exclusively within the United States. Further information and product details are available on the company’s website: www.vivoslife.com .
